We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Launch of Organs-on-a-Chip
Product News

Launch of Organs-on-a-Chip

Launch of Organs-on-a-Chip
Product News

Launch of Organs-on-a-Chip


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Launch of Organs-on-a-Chip"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Hundreds of micro-organs mimicked on a chip, with minuscule channels that serve as blood vessels. These devices can raise drug development to a new level and reduce animal testing.

Leiden researchers and their spin-off company Mimetas are set to launch their ’organs-on-a-chip’, backed by a 200,000 euro subsidy from STW.

Revolutionizing drug development
'We mimic human organs in a microscopically small space,' explains LACDR researcher and Mimetas co-founder Paul Vulto.

Vulto continued, 'These organs-on-a-chip can be used to determine the efficacy and toxic side-effects of new medicines better and faster. They provide a unique, novel bridge between traditional laboratory tests and clinical testing in patients. Showing closer resemblance to humans, they have the potential to revolutionize therapeutic drug development and save many laboratory animals at the same time.'

Personalized medicine
One Mimetas device fits hundreds of micro-organs in which tiny microfluidic channels act as blood vessels. Currently, Mimetas develops its products to help pharmaceutical companies make better medicines at lower costs.

Ultimately, Mimetas products will be used to select the best therapy for individual patients, based on direct testing of drugs on diseased cells, so-called personalized medicine.

200,000 euro subsidy
Mimetas is the result of research and business development efforts by Paul Vulto, Thomas Hankemeier and Bas Trietsch from the University of Leiden and biotech-entrepreneur Jos Joore.

Research has been performed within and with support of the Division of Analytical Biosciences and the Netherlands Metabolomics Centre.

Advertisement